142 related articles for article (PubMed ID: 37334524)
1. Single-cell transcriptome analysis reveals cellular and molecular alterations in small cell lung cancer tumors following chemotherapy.
Cheng C; Zhu G; Li Y; Wang H; Wang S; Li C; Feng J; Wang Z; Li W
Int J Cancer; 2023 Sep; 153(6):1273-1286. PubMed ID: 37334524
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M; Yoshida T; Shiraishi K; Goto N; Yagishita S; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Naoki K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
Br J Cancer; 2023 Dec; 129(12):2003-2013. PubMed ID: 37731022
[TBL] [Abstract][Full Text] [Related]
3. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J; Cao D; Sha J; Zhu X; Han S
Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
[TBL] [Abstract][Full Text] [Related]
4. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
[TBL] [Abstract][Full Text] [Related]
6. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
[TBL] [Abstract][Full Text] [Related]
7. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
[TBL] [Abstract][Full Text] [Related]
8. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer.
Tian Y; Li Q; Yang Z; Zhang S; Xu J; Wang Z; Bai H; Duan J; Zheng B; Li W; Cui Y; Wang X; Wan R; Fei K; Zhong J; Gao S; He J; Gay CM; Zhang J; Wang J; Tang F
Signal Transduct Target Ther; 2022 Oct; 7(1):346. PubMed ID: 36195615
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.
Zhang H; Yang Y; Li X; Yuan X; Chu Q
Biomed Pharmacother; 2023 Mar; 159():114248. PubMed ID: 36645960
[TBL] [Abstract][Full Text] [Related]
10. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
11. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Wermke M; Felip E; Gambardella V; Kuboki Y; Morgensztern D; Hamed ZO; Liu M; Studeny M; Owonikoko TK
Future Oncol; 2022 Aug; 18(24):2639-2649. PubMed ID: 35815644
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
14. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting RORγ with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate.
Chen J; Hu Y; Zhang J; Wang Q; Wu X; Huang W; Wang Q; Cai G; Wang H; Ou T; Feng W; Liu P; Liu Y; Wang J; Huang J; Wang J
Pharmacol Res; 2022 Apr; 178():106160. PubMed ID: 35259480
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
Song Y; Sun Y; Sun T; Tang R
Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
[TBL] [Abstract][Full Text] [Related]
17. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
[TBL] [Abstract][Full Text] [Related]
19. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
